ESMO 2016. LBA14_PR. FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer J. Ellis et al. Results: In total, 462 patients...

There have been significant changes in the CLL treatment landscape with the approval of novel targeted therapies and greater understanding of how molecular and mutation status can guide treatment decisions....

Among the exciting data presented at ASH in December 2018 were updates from two trials which are anticipated to have an impact on how relapsed/refractory multiple myeloma (R/R MM) is...

Depuis 54 ans, la Fédération des sciences neurologiques du Canada (CNSF) tient un congrès annuel incluant des présentations sur les progrès réalisés en neurologie. Le comité académique de CARE™ s’intéresse...

For the past 54 years, the Canadian Neurological Sciences Federation (CNSF) has held an annual meeting that features presentations on advances in neurology. The CARE™ Faculty focuses on key news...

This CARE™ Perspectives report covers both ASCO and EHA 2019. (The 2019 annual ASCO meeting was held on May 31 - June 4, 2019 in Chicago, with EHA following on...

In the lead up to ASCO 2019, the results of several late stage clinical trials on metastatic hormone sensitive prostate cancer (mHSPC) were released. For Canadian clinicians the results are...

Members of the CARE™ Oncology faculty attended the American Society of Clinical Oncology (ASCO 2019) annual meeting from May 31st – June 4th in Chicago, IL and the Canadian Urological...

Members of the CARE™ Oncology faculty attended the American Society of Clinical Oncology (ASCO 2019) annual meeting from May 31st – June 4th in Chicago, IL. While ASCO 2019 featured coverage...

This CARE™ prostate cancer section of the CARE™ Perspectives from ASCO 2019 Report features select prostate cancer highlights from content presented at the 2019 ASCO Annual Meeting (abridged section). Recent...